Using treatment response to subtype schizophrenia: Proposal for a new paradigm in classification

Schizophrenia Bulletin

Volumn 39, Issue 6, 2013, Pages 1169-1172

  Farooq, Saeed ^a,b   Agid, Ofer ^c   Foussias, George ^c,d   Remington, Gary ^c,d  

^a STAFFORDSHIRE UNIVERSITY   (United Kingdom)

^b LADY READING HOSPITAL   (Pakistan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; FACE VALIDITY; HUMAN; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

HUMANS; SCHIZOPHRENIA;

EID: 84886068319     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt137     Document Type: Review

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. World Health Organization. ICD-10 Classification of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
3. Gaebel W. Status of psychotic disorders in ICD-11. Schizophr Bull. 2012;38:895-898.
4. Tandon R, Carpenter WT Jr. DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull. 2012;38:369-370.
5. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167:748-751.
6. Gonnella JS, Hornbrook MC, Louis DZ. Staging of disease. A case-mix measurement. JAMA. 1984;251:637-644. (Pubitemid 14221027)
7. Wood SJ, Yung AR, McGorry PD, Pantelis C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol Psychiatry. 2011;70:619-625.
8. Mathalon DH. Challenges associated with application of clinical staging models to psychotic disorders. Biol Psychiatry. 2011;70:600-601.
9. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland: WHO Press; 2010.
10. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7(suppl 5):20-28.
11. Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012;2012:974594.
12. Mathalon DH, Ford JM. Neurobiology of schizophrenia: search for the elusive correlation with symptoms. Front Hum Neurosci. 2012;6:136.
13. Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs. 2008;13:479-495.
14. Leucht S, Davis JM. Are all antipsychotic drugs the same? Br J Psychiatry. 2011;199:269-271.
15. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011;72:1439-1444.
16. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549. (Pubitemid 29162974)
17. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
18. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151:1744-1752. (Pubitemid 24370894)
19. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl). 1989;99(suppl):S68-S72. (Pubitemid 19244143)
20. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2004;161(suppl):1-140.
21. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001;50:898-911. (Pubitemid 34020701)
22. Mouaffak F, Tranulis C, Gourevitch R, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006;29:28-33. (Pubitemid 44378609)
23. Kapur S, Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873-883. (Pubitemid 34020700)
24. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
25. Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci. 2003;28:275-284. (Pubitemid 37153435)
26. Pandina G, Bilder R, Turkoz I, Alphs L. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder. Schizophr Res. 2013;143:312-318.
27. Remington G, Foussias G, Agid O, Takeuchi T, Rao N. Anti-schizophrenia drugs: the next generation. JPPS. 2012;9:49-52.
28. Laughren TP. What's next after 50 years of psychiatric drug development: an FDA perspective. J Clin Psychiatry. 2010;71:1196-1204.
29. Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry. 2011;199:281-288.
30. Remington G. Augmenting clozapine response in treatment-resistant schizophrenia. In: Elkis H, Meltzer, HY, eds. Therapy-Resistant Schizophrenia. Basel, Switzerland: Karger; 2010:129-151.
31. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32:1903-1910. (Pubitemid 47258518)
32. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449. (Pubitemid 40343909)
33. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory metaanalysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222. (Pubitemid 41070936)
34. Levy E, Pawliuk N, Joober R, Abadi S, Malla A. Medicationadherent first-episode psychosis patients also relapse: why? Can J Psychiatry. 2012;57:78-84.
35. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170:609-615.
36. Levander S, Jensen J, Grawe R, Tuninger E. Schizophrenia-progressive and massive decline in response readiness by episodes. Acta Psychiatr Scand Suppl. 2001;408:65-74.
37. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9. (Pubitemid 26327751)
38. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010;68:86-92.
39. Karow A, Moritz S, Lambert M, Schöttle D, Naber D; EGOFORS Initiative. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia. Eur Psychiatry. 2012;27:401-405.
40. Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry. 2011;198:247-249.